Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1175611.RAamwi68etS72WKXwPPL3gkM1ZkYsmflBy9c3RN7m9tTc130_assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175611.RAamwi68etS72WKXwPPL3gkM1ZkYsmflBy9c3RN7m9tTc130_provenance.
• NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175616.RARkkoIkIHZgK3fCR0rGWAqiB_k2_Adi2BSI5256AESIA130_provenance.
• NP1175622.RAVIF3KMRWM81W8BHPDDxrWhORmjLpKF5Id5ENu_f06q0130_assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175622.RAVIF3KMRWM81W8BHPDDxrWhORmjLpKF5Id5ENu_f06q0130_provenance.
• NP1175623.RAVAucjiVVia4mk_ryS53KqaGeYZh6IfZLcHt26Cci0O8130_assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175623.RAVAucjiVVia4mk_ryS53KqaGeYZh6IfZLcHt26Cci0O8130_provenance.
• NP1175617.RABMWGlEPD5Ya4FMzDibOaVqOULgtTJTh18wHnZB_-x8o130_assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175617.RABMWGlEPD5Ya4FMzDibOaVqOULgtTJTh18wHnZB_-x8o130_provenance.
• NP1175618.RAyGZiKXqpcZ20u0LZN7NUXFBw8qRfZqAnrBqTawsw2C4130_assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175618.RAyGZiKXqpcZ20u0LZN7NUXFBw8qRfZqAnrBqTawsw2C4130_provenance.
• NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_provenance.
• NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_provenance.